Selling Ocular Therapeutix Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders
The article "Selling Ocular Therapeutix Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders" analyzes insider transactions for Ocular Therapeutix, Inc. (NASDAQ:OCUL). It suggests that recent insider selling at prices lower than the current market value might have been a missed opportunity for the insiders given potential stock appreciation. The article likely delves into specific transaction details and financial implications for the company and its insiders.
Can Ocular Therapeutix's (OCUL) Rising Losses on Flat Revenue Still Support Its R&D Ambitions?
Ocular Therapeutix (OCUL) recently reported Q1 2026 results with nearly flat revenue but a significantly wider net loss, driven by substantial R&D investments in its ophthalmology pipeline. The company's investment narrative heavily relies on the success of its lead product, AXPAXLI, which has shown promising trial data. While clinical progress is encouraging, increasing losses and dependence on AXPAXLI's approval path raise concerns for investors, especially with analysts already forecasting strong revenue growth but no profits in the near term.
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors
Saturn V Capital Management fully exited its position in Ocular Therapeutix (NASDAQ:OCUL), selling 1,504,880 shares for an estimated $14.34 million. This move represents a complete divestment, signaling potential concerns about the company's financial performance despite some positive clinical trial data. Ocular Therapeutix, a biopharmaceutical company, recently reported widening losses and lighter-than-hoped revenue, leading to investor skepticism.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. announced inducement awards granted to Ms. Amy Ricca, their new SVP, Head of HR, under Nasdaq Listing Rule 5635(c)(4). These awards, effective May 11, 2026, include stock options to purchase up to 75,000 shares and restricted stock units for 25,000 shares, serving as an inducement for her employment. The grants are subject to vesting schedules and the terms of Ocular’s 2019 Inducement Stock Incentive Plan.
[SCHEDULE 13G/A] OCULAR THERAPEUTIX, INC Amended Passive Investment Disclosure
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed an amended passive investment disclosure (Schedule 13G/A) for Ocular Therapeutix, Inc. They report beneficial ownership of 20,850,000 shares of common stock, representing 9.53% of the class as of March 31, 2026. This includes 1,163,718 Pre-Funded Warrants subject to a 9.99% maximum exercise limitation.
New HR boss at Ocular Therapeutix lands 75,000 stock options, 25,000 RSUs
Ocular Therapeutix (NASDAQ: OCUL) has granted inducement equity awards to its new SVP, Head of HR, Amy Ricca. These awards, made under Nasdaq Listing Rule 5635(c)(4), include non-statutory stock options for 75,000 shares at an exercise price of $9.28 and 25,000 restricted stock units, both with multi-year vesting schedules. The grants aim to incentivize Ricca and align her long-term interests with the company's performance, subject to her continued employment.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced inducement grants to Ms. Amy Ricca, the new SVP, Head of HR, under Nasdaq Listing Rule 5635(c)(4). These awards, effective May 11, 2026, include a stock option for up to 75,000 shares and restricted stock units for 25,000 shares, vesting over several years contingent on her continued employment. The company also provided an overview of its biopharmaceutical pipeline, including AXPAXLI™ for retinal diseases and DEXTENZA® for ocular inflammation.
A Look At Ocular Therapeutix (OCUL) Valuation After Recent Share Price Pullback
Ocular Therapeutix (OCUL) has experienced a recent stock pullback despite a 30.86% one-year total shareholder return, prompting a re-evaluation of its valuation. While a popular narrative suggests the stock is 64.8% undervalued with a fair value of $26.00, largely due to the anticipated approval of AXPAXLI, another view highlights significant valuation risk with a P/S ratio of 38.5x compared to an industry average of 4.8x. Investors are encouraged to consider both the potential rewards and warning signs before making a decision.
Ocular Therapeutix, Inc. $OCUL Shares Bought by Empire Life Investments Inc.
Empire Life Investments Inc. significantly increased its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 115% in Q4, now holding over 540,000 shares worth $6.6 million, contributing to the high institutional ownership of 59.21%. Insider activity shows Director Richard L. Md Lindstrom purchasing shares, while insider Pravin Dugel sold a portion of his holdings. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $23.78 for the biopharmaceutical company.
Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Dole PLC experienced a sharp decline in pre-market trading after reporting lower-than-expected Q1 adjusted EPS, though sales surpassed estimates. Several other companies, including Enhanced Group, Phoenix Asia Holdings, and Cracker Barrel Old Country Store, also saw their stock prices drop in pre-market trading. These movements occurred as U.S. stock futures showed a slight dip on Monday.
Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's P
Dole PLC shares fell significantly in pre-market trading after the company reported lower-than-expected adjusted EPS for the first quarter, though sales beat estimates. Several other stocks, including Enhanced Group, Phoenix Asia Holdings, Cracker Barrel, and Canadian Solar, also experienced declines in pre-market trading, with some reacting to previous day's gains or upcoming earnings reports. Ocular Therapeutix Inc. also declined after reporting inducement grants.
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix, Inc. announced inducement grants to twelve new non-executive employees, consisting of stock options for 127,650 shares and restricted stock units for 41,550 shares. These awards were made under the company's 2019 Inducement Stock Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4), to attract new talent. The grants vest over three to four years, subject to continued employment, and the stock options were priced at $9.71 per share.
Twelve new Ocular employees get stock awards tied to 169,200 shares
Ocular Therapeutix (NASDAQ: OCUL) granted inducement equity awards to twelve new non-executive employees on May 4, 2026. These awards include non-statutory stock options for 127,650 shares and restricted stock units for 41,550 shares, with an option exercise price of $9.71 per share. The grants were made under the company's 2019 Inducement Stock Incentive Plan, aligning new hires with multi-year vesting schedules.
Ocular Therapeutix Price Target Maintained With a $18.00/Share by Needham
Needham has reiterated its "Buy" rating for Ocular Therapeutix and maintained a price target of $18.00 per share. This indicates the firm's continued confidence in the company's stock performance.
Ocular: SOL-1 Success Is Real, But Adoption Risks Keep Me At Hold (NASDAQ:OCUL)
Ocular Therapeutix's current valuation for Axpaxli, an insert for wet AMD and NPDR, reflects optimistic adoption assumptions despite SOL-1 data meeting primary endpoints. The author maintains a "Hold" rating due to doubts about broad adoption by retinal specialists based on current evidence, highlighting the upcoming SOL-R trial as crucial for assessing Axpaxli's competitiveness. A scenario analysis suggests the stock is currently trading closer to a bull case than a base case.
Ocular Therapeutix (OCUL) Heavy Losses Challenge Bullish Growth Narratives In Q1 2026 Earnings
Ocular Therapeutix (OCUL) reported Q1 2026 earnings with $52 million in trailing twelve-month revenue but a significant loss of $266 million, resulting in a Basic EPS loss of $1.42. The company faces challenges with widening losses over five years, high cash burn, and projected dilution, despite strong revenue growth forecasts and a high Price/Sales ratio. Investors are left to weigh the promising growth narrative against the ongoing unprofitability and financing risks.
Ocular Therapeutix reports Q1 EPS (40c), consensus (31c)
Ocular Therapeutix (OCUL) reported first-quarter EPS of (40c), missing the consensus estimate of (31c), with revenue of $10.79M, below the $12.7M consensus. Despite the earnings miss, the company highlighted the positive results from its AXPAXLI SOL-1 Phase 3 trial for wet AMD, emphasizing the drug's superiority and potential to transform treatment. Ocular Therapeutix plans to submit a New Drug Application (NDA) based on the trial data and is preparing for commercialization.
Earnings call transcript: Ocular Therapeutix Q1 2026 shows earnings miss
Ocular Therapeutix (OCUL) reported a significant earnings miss in Q1 2026, with EPS of -$0.40 against a forecasted -$0.31, and revenue of $10.78 million versus predicted $12.72 million. Despite the financial shortfall, the company maintains a strong cash position and is advancing its product pipeline, particularly AXPAXLI for wet AMD, with an NDA submission planned based on promising clinical trial results. Executives discussed ongoing formal discussions with the FDA regarding regulatory approval for AXPAXLI and future clinical trials to evaluate long-term outcomes and commercialization strategies.
Ocular Therapeutix 1Q 2026: Revenue $10.79M, Net income ($88.61M), EPS ($0.4) — 10-Q Summary
Ocular Therapeutix reported its first-quarter 2026 results, showing a slight increase in revenue to $10.79 million but a larger net loss of ($88.61 million) compared to the prior year. The company highlighted positive clinical trial results for SOL-1, progress in its pipeline with upcoming topline data for SOL-R, and modest commercial growth for DEXTENZA. Increased R&D spending is supporting registrational trials and NDA preparation for AXPAXLI.
[10-Q] OCULAR THERAPEUTIX, INC Quarterly Earnings Report
OCULAR THERAPEUTIX, INC (OCUL) has filed its Quarterly Earnings Report (10-Q) for the period ended March 31, 2026. The company reported a net loss of $88.6 million for the quarter, an increase from $64.05 million in the same period last year. Revenue saw a slight increase to $10.78 million from $10.69 million, driven by product revenue, while research and development expenses significantly rose to $66.2 million.
Ocular Therapeutix reports Q1 2026: $10.8M revenue, $88.6M net loss, $666.7M cash
Ocular Therapeutix reported their first-quarter 2026 results, showing total net revenue of $10.8 million and a net loss of $88.6 million. The company holds $666.7 million in cash and cash equivalents, which is expected to fund operations into 2028. Key business highlights include positive Phase 3 SOL-1 results for AXPAXLI and intentions to submit a New Drug Application.
Ocular Therapeutix (NASDAQ: OCUL) widens Q1 loss while advancing AXPAXLI Phase 3 trials
Ocular Therapeutix reported a wider net loss of $88.6 million in Q1 2026, compared to $64.1 million in Q1 2025, primarily due to increased R&D spending on its AXPAXLI Phase 3 trials. Despite the increased loss, the company announced positive Phase 3 SOL-1 results for AXPAXLI in wet AMD, meeting superiority endpoints and supporting plans for an NDA submission. Ocular Therapeutix maintains a strong cash position of $666.7 million, expected to fund operations into 2028, encompassing ongoing trials and pre-commercialization efforts for AXPAXLI.
Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights
Ocular Therapeutix, Inc. reported its first-quarter 2026 financial results, highlighted by significant progress in its AXPAXLI clinical trials for wet AMD and diabetic retinopathy. The company announced positive Phase 3 SOL-1 results demonstrating AXPAXLI's superiority, accelerated commercial preparedness plans, and ongoing enrollment in extension trials. Ocular Therapeutix also maintains a strong cash balance of $666.7 million, with an expected runway into 2028.
Ocular Therapeutix: Q1 Earnings Snapshot
Ocular Therapeutix Inc. (OCUL) reported a first-quarter loss of $88.6 million, or 40 cents per share, missing Wall Street expectations. Adjusted losses were 41 cents per share, while analysts had predicted a loss of 32 cents per share. The biotechnology company's revenue of $10.8 million also fell short of the $12.7 million forecast by analysts.
Ocular Therapeutix: Q1 Earnings Snapshot
Ocular Therapeutix Inc. (OCUL) reported a first-quarter loss of $88.6 million, or 40 cents per share, missing Wall Street expectations. Adjusted losses were 41 cents per share, compared to an average analyst estimate of 32 cents per share. The biotechnology company also reported revenue of $10.8 million, falling short of the $12.7 million forecast by analysts.
Ocular Therapeutix Q1 2026 earnings preview
This article provides a preview of Ocular Therapeutix's Q1 2026 earnings. It is a placeholder indicating that a detailed earnings preview will be available soon.
Assessing Ocular Therapeutix (OCUL) Valuation After New AXPAXLI Trial Progress And FDA Preparation
Ocular Therapeutix (OCUL) is under evaluation after enrolling the first patient in its SOL-X trial for AXPAXLI and continuing FDA discussions for wet age-related macular degeneration. Despite recent clinical progress and a positive narrative valuation of $26 per share, the company's stock has experienced volatility, and its high P/S ratio (39.5x) suggests that current expectations may have outpaced revenue generation. The success of AXPAXLI in clearing regulatory hurdles and achieving market adoption will be crucial for validating its long-term potential and justifying its current valuation.
Ocular Therapeutix earnings up next as AXPAXLI NDA looms
Ocular Therapeutix Inc. is set to announce its first-quarter earnings, with investor attention primarily focused on the company's progress toward filing a regulatory application for AXPAXLI, its experimental wet age-related macular degeneration treatment. Despite projected losses, analysts maintain a bullish outlook due to the drug's promising Phase 3 trial results and potential for high upside. The revenue performance of the company's only marketed product, DEXTENZA, will also be scrutinized.
Assessing Ocular Therapeutix (OCUL) Valuation After New AXPAXLI Trial Progress And FDA Preparation
Ocular Therapeutix (OCUL) is in focus after new trial progress for its wet AMD drug, AXPAXLI, and ongoing FDA discussions. Analysts project a significantly undervalued stock at $26 based on AXPAXLI's potential market share in a growing population, despite the company currently trading at $9.43 with high P/S ratios compared to the industry. The valuation hinges on successful clinical and regulatory hurdles for AXPAXLI and strong market uptake.
What Ocular Therapeutix (OCUL)'s SOL-X Long-Term AXPAXLI Extension Study Means For Shareholders
Ocular Therapeutix has initiated its SOL-X long-term extension study for AXPAXLI, a critical step that could broaden the therapy's clinical and commercial appeal for wet age-related macular degeneration. The study aims to evaluate long-term safety, efficacy, and disease-modifying potential. This development is key to the company's investment narrative, which heavily relies on AXPAXLI's success and an upcoming NDA outcome, despite current losses and a premium valuation.
[ARS] OCULAR THERAPEUTIX, INC SEC Filing
This article announces an ARS SEC filing by Ocular Therapeutix, Inc. (OCUL) on April 30, 2026. The filing is available as a PDF document and contains an Annual Report to Security Holders. The article also provides recent news and other SEC filings related to Ocular Therapeutix, along with key stock data.
Ocular Therapeutix (NasdaqGM:OCUL) Stock Forecast & Analyst Predictions
Ocular Therapeutix is forecast to see significant earnings and revenue growth, with analysts frequently updating their price targets based on detailed Phase 3 SOL-1 data for Axpaxli, their lead drug candidate. The company's recent pipeline developments and potential acquisition interest from Sanofi are driving increased optimism and revised fair value estimates among analysts, despite the company being projected to remain unprofitable for the next three years.
First wet AMD patient enters 3-year AXPAXLI follow-up study
Ocular Therapeutix (NASDAQ: OCUL) announced that the first patient has been enrolled in SOL-X, a three-year open-label long-term extension trial for AXPAXLI (OTX-TKI) in wet age-related macular degeneration (wet AMD). This study aims to evaluate AXPAXLI's long-term safety, sustained VEGF suppression, and potential to improve long-term visual outcomes by reducing treatment burden in patients who completed previous 2-year trials (SOL-1 or SOL-R). The company believes AXPAXLI has the potential to fundamentally alter the trajectory of the disease and significantly expand the number of patients who remain on therapy.
Ocular Therapeutix enrolls first patient in wet AMD extension trial
Ocular Therapeutix Inc. (NASDAQ:OCUL) has enrolled the first patient in its SOL-X long-term extension trial for AXPAXLI, a treatment for wet age-related macular degeneration. The trial will assess the long-term safety and efficacy of AXPAXLI, with patients receiving injections every 24 weeks. Despite being unprofitable, the company maintains a strong balance sheet and is seen as undervalued by InvestingPro.
Ocular Therapeutix enrolls first patient in wet AMD extension trial By Investing.com
Ocular Therapeutix has enrolled the first patient in its SOL-X long-term extension trial for AXPAXLI, an investigational treatment for wet age-related macular degeneration. The trial aims to evaluate the long-term safety and efficacy of AXPAXLI, a bioresorbable intravitreal hydrogel, in patients who completed previous studies. Despite being unprofitable, the company has strong analyst support and a solid balance sheet, with its stock appearing undervalued according to InvestingPro.
Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD
Ocular Therapeutix announced the enrollment of the first patient in its SOL-X long-term extension trial for AXPAXLI (OTX-TKI), an investigational treatment for wet age-related macular degeneration (wet AMD). This trial builds upon the successful SOL-1 Phase 3 study and aims to evaluate the long-term safety and efficacy of AXPAXLI, focusing on its potential to improve visual outcomes and reduce treatment burden. The company believes that continuous VEGF suppression with AXPAXLI could fundamentally alter the disease trajectory by mitigating risks associated with current pulsatile therapies.
Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD
Ocular Therapeutix™ announced the enrollment of the first patient in its SOL-X long-term extension trial for AXPAXLI™ (OTX-TKI) in wet age-related macular degeneration (wet AMD). This trial builds on the success of the SOL-1 Phase 3 study, aiming to evaluate the long-term safety and efficacy of AXPAXLI and its potential to improve visual outcomes with reduced treatment burden. The company believes continuous VEGF suppression offered by AXPAXLI can fundamentally alter the disease trajectory and improve patient retention.
Ocular Therapeutix Inc. (OCUL) Appears Highly Attractive Following SOL-1 Clinical Trial Data
Ocular Therapeutix Inc. (NASDAQ: OCUL) is gaining attention as a top biotech stock with high upside potential, following positive additional SOL-1 clinical trial data. William Blair maintained an Outperform rating, highlighting Axpaxli’s effectiveness and durability in treating eye conditions. The company is progressing towards submitting a New Drug Application based on these promising results for its bioresorbable hydrogel-based therapeutics.
Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026
Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced it will host a conference call and webcast on Tuesday, May 5, 2026, at 8:00 AM ET to discuss its first-quarter 2026 financial results and recent business progress. The company is a biopharmaceutical firm focused on retinal diseases, with investigational products like AXPAXLI™ in Phase 3 clinical trials.
Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences
Ocular Therapeutix, Inc. announced its participation in several scientific and investor conferences throughout May 2026. Executive Chairman, President and CEO, Pravin U. Dugel, will present at the Bank of America Health Care Conference and the Stifel 2026 Virtual Ophthalmology Forum. Additionally, the company will have presentations and posters at Eyecelerator @ ARVO 2026, ARVO 2026 Annual Meeting, Retina World Congress 2026, and The Royal College of Ophthalmologists Annual Congress 2026, focusing on its investigational product AXPAXLI™ for retinal diseases.
Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026
Ocular Therapeutix, Inc. will host a conference call and webcast on Tuesday, May 5, 2026, at 8:00 AM ET to discuss its first quarter 2026 financial results and recent business progress. The biopharmaceutical company, which is focused on redefining the retina experience, will provide investors and media with an update on its investigational product candidate AXPAXLI for retinal diseases and its commercial product DEXTENZA.
Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026
Ocular Therapeutix, Inc. announced its plan to host a conference call and webcast on May 5, 2026, at 8:00 AM ET, to discuss its first-quarter 2026 financial results and recent business progress. The company is a biopharmaceutical firm focused on retinal diseases, with products like AXPAXLI™ in Phase 3 trials and the FDA-approved DEXTENZA®. The webcast details and company information are provided for investors and media.
Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026
Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced it will host a conference call and webcast on Tuesday, May 5, 2026, at 8:00 AM ET. The company will discuss its recent business progress and financial results for the first quarter ended March 31, 2026. Details for accessing the call and webcast are provided, along with information about Ocular Therapeutix and its pipeline products.
May 5 at 8 a.m. ET: Ocular Therapeutix to discuss Q1 results
Ocular Therapeutix (NASDAQ: OCUL) will announce its first-quarter 2026 financial results on May 5, 2026, followed by a conference call and webcast at 8:00 AM ET. The company will discuss its business progress and financial performance for the quarter ended March 31, 2026. This announcement follows several recent communications regarding clinical updates and investor events.
Ocular Therapeutix Says FDA Talks Progressing as It Eyes AXPAXLI NDA for Wet AMD on SOL-1 Data
Ocular Therapeutix is in formal discussions with the FDA regarding a New Drug Application (NDA) for AXPAXLI in wet age-related macular degeneration (wet AMD), based on the single, rigorously designed SOL-1 Phase 3 trial which met its primary endpoint with robust statistical significance and a favorable safety profile. The company aims for a superiority label and plans independent commercialization, supported by strong IP and scalable manufacturing. Ocular Therapeutix believes a single-trial approval is possible given the robust design of SOL-1 and favorable FDA signals.
Ocular lines up May talks on AMD trial data and investor webcasts
Ocular Therapeutix (NASDAQ: OCUL) announced its participation in multiple scientific and investor conferences throughout May 2026. The company plans to present key Phase 3 OTX-TKI SOL-1 trial results, provide updates on its TKI program, and share real-world anti-VEGF analyses. Webcasts for investor conferences will be available on the company's investor relations page.
Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences
Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced its participation in multiple scientific and investor conferences throughout May 2026. The company's Executive Chairman, President, and CEO, Pravin U. Dugel, MD, will present at the Bank of America Health Care Conference and the Stifel Virtual Ophthalmology Forum. Key scientific presentations will cover trial results for their investigational product AXPAXLI, targeting neovascular age-related macular degeneration, at events like ARVO and Retina World Congress.
Ocular Therapeutix prices $475M stock offering
Ocular Therapeutix has priced its stock offering at $475 million. This financial move is noteworthy for the company.
Ocular Therapeutix (OCUL) Is Up 8.2% After Positive Phase 3 AXPAXLI Data and FDA Feedback - What's Changed
Ocular Therapeutix (OCUL) shares increased by 8.2% following positive Week 52 data from its Phase 3 SOL-1 trial for AXPAXLI, showing superior durability and sustained disease control in wet AMD patients. The company also received FDA feedback supporting a single-trial approval pathway, which could expedite the NDA filing. This development significantly strengthens Ocular Therapeutix's investment narrative, with an upcoming Investor Day expected to clarify regulatory timing, cash runway, and commercialization plans.
Ocular Therapeutix (OCUL) Is Up 8.2% After Positive Phase 3 AXPAXLI Data and FDA Feedback - What's Changed
Ocular Therapeutix (OCUL) saw an 8.2% stock price increase following positive Week 52 data from its Phase 3 SOL-1 trial for AXPAXLI, which demonstrated superior durability and sustained disease control in wet AMD patients. Furthermore, feedback from the FDA supports the company's plan to seek approval based on this single Phase 3 trial, potentially accelerating the NDA filing process. This development could significantly enhance Ocular Therapeutix's investment outlook by sharpening the regulatory catalyst and offering a clearer path to market for AXPAXLI.
